Individualización del tratamiento de la diabetes mellitus tipo 2

  1. Llavero Valero, M. 1
  2. Ugalde, B. 1
  3. Huguet, I. 1
  4. Triviño, V. 1
  1. 1 Servicio de Endocrinología y Nutrición, Hospital Universitario Infanta Leonor, Madrid, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Actualidad clínico-terapéutica (II)

Series: 13

Issue: 46

Pages: 2688-2697

Type: Article

DOI: 10.1016/J.MED.2021.12.003 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

The rising incidence of type 2 diabetes mellitus (DM2) nowadays represents a true public health problem and there is a need to improve this disease's prognosis. In recent years, a glucocentric treatment approach has progressively been abandoned, giving way to a comprehensive approach to the patient that allows for the individualization of treatment, given the high degree of heterogeneity among diabetic patients. In this regard, multiple aspects must be considered when choosing a treatment (age, life expectancy, patient preferences, etc.). However, nowadays, the presence of cardiovascular disease, chronic kidney disease, or heart failure condition treatment choice to a great extent, given the cardiovascular benefits obtained from new families of antidiabetic drugs (GLP-1 receptor agonists and SGLT2 inhibitors).

Bibliographic References

  • Gil Gregorio P. Criterios diagnósticos. Beneficios del diagnóstico precoz. Rev Esp Geriatría Gerontol. 2016;51:7-11.
  • Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: A review. JAMA. 2019;322(16):1589-99.
  • Scheltens P, Strooper BD, Kivipelto M, Holstege H, Chételat G, Teunissen CE. Alzheimer’s disease. The Lancet. 2021;397 (10284):1577-90.
  • Manzano MS, Fortea J, Villarejo A, Sánchez del Valle R. Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2018. 5. Guía oficial de práctica clínica en demencias. Madrid: Sociedad Española de Neurología (SEN); 2018.
  • Busse A, Bischkopf J, Riedel Heller SG, Angermeyer MC. Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged (LEI-LA75+). Br J Psychiatry J Ment Sci. 2003;182:449-54.
  • Rodríguez JG, Gutiérrez GG. Definición y prevalencia del deterioro cognitivo leve. Rev Esp Geriatría Gerontol Organo of Soc Esp Geriatría Gerontol. 2017;52(Extra1):3-6.
  • Olmo JG. Epidemiología de la enfermedad de Alzheimer y otras demencias. Rev Neurol. 2018;66(11):377-86.
  • Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30(3):421-42.
  • Long JM, Holtzman DM. Alzheimer Disease: An update on pathobiology and treatment strategies. Cell. 2019;179(2):312-39.
  • Harada CN, Natelson Love MC, Triebel K. Normal cognitive aging. Clin Geriatr Med. 2013;29(4):737-52.
  • Skrobot OA, Black SE, Chen C, DeCarli C, Erkinjuntti T, Ford GA. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the vascular impairment of cognition classification consensus study. Alzheimers Dement J Alzheimers Assoc. 2018;14(3):280-92.
  • Jellinger KA. Avances en la fisiopatología de la demencia vascular. Rev Esp Geriatría Gerontol. 2004;39(1):41-9.
  • Johnson JCS, McWhirter L, Hardy CJD, Crutch SJ, Marshall CR, Mummery CJ. Suspecting dementia: canaries, chameleons and zebras. Pract Neurol. 2021;21(4):300-12.
  • Bottino CMC, de Pádua AC, Smid J, Areza Fegyveres R, Novaretti T, Bahia VS. Differential diagnosis between dementia and psychiatric disorders: Diagnostic criteria and supplementary exams. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol. 2011;5(4): 288-96.
  • Pask S, Dell’Olio M, Murtagh FEM, Boland JW. The effects of opioids on cognition in older adults with cancer and chronic noncancer pain: A systematic review. J Pain Symptom Manage. 2020;59(4):871-893.e1.
  • Health Quality Ontario. Vitamin B12 and cognitive function: an evidence-based analysis. Ont Health Technol Assess Ser. 2013;13(23):1-45.
  • Barquero Toledo M, Carnero Pardo C, Martínez Lozano MD. Clasificación. En: Molinuevo JL, Peña Casanova J, editores. Guía oficial de la Sociedad Española de Neurología (SEN) para la práctica clínica en de-mencias: conceptos, criterios y recomendaciones. Barcelona: Thomson Reuters; 2009. p. 51-60.
  • Carlsson CM, Gleason CE, Puglielli L, Asthana S. Dementia including Alzheimer’s Disease. Hazzard’s Geriatric Medicine and Gerontology. 6ª ed. New York: McGraw-Hill Education; 2008. p. 797-811.
  • O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698-706.
  • Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683-97.
  • Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet Lond Engl. 2015;386(10004):1672-82.
  • Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. The BMJ. 2015;350: h369.
  • Olazaran Rodríguez J, Aguera Ortiz LF, Muniz Schwochert R. [Psychological and behavioural symptoms of dementia: prevention, diagnosis and treatment]. Rev Neurol. 2012;55(10):598-608.
  • Mitchell SL, Jones RN, Prigerson HG, Hamel MB. The clinical course of advanced dementia. N Engl J Med. 2009;10.
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):263-9.
  • Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2018;14(4): 535-62.
  • Overview dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97]. 2018.
  • Bahar Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;3:CD013069.
  • Demurtas J, Schoene D, Torbahn G, Marengoni A, Grande G, Zou L. Physical activity and exercise in mild cognitive impairment and dementia: An umbrella review of intervention and observational studies. J Am Med Dir Assoc. 2020;21(10):1415-22.e6.
  • Rodríguez D, Formiga F, Fort I, Robles MJ, Barranco E, Cubí D; Grupo de Trabajo de Demencias de la Sociedad Catalana de Geriatría y Gerontología. Tratamiento farmacológico de la demencia: cuándo, cómo y hasta cuándo. Recomendaciones del Grupo de Trabajo de Demencias de la Sociedad Catalana de Geriatría y Gerontología. Rev Esp Geriatr Gerontol. 2012;47(5):228-33.
  • Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol. 2015;22(6):889-98.
  • McCleery J, Quinn TJ. Aducanumab and the certainty of evidence. Age Ageing. 2021:afab167.
  • Gerlach LB, Kales HC. Managing behavioral and psychological symptoms of dementia. Clin Geriatr Med. 2020;36(2):315-27.
  • O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-8.
  • Kongpakwattana K, Sawangjit R, Tawankanjanachot I, Bell JS, Hilmer SN, Chaiyakunapruk N. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84(7):1445-56.
  • Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.
Data source: Dialnet